...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Moringa concanensis Nimmo ameliorates hyperglycemia in 3T3-L1 adipocytes by upregulating PPAR-gamma, C/EBP-alpha via Akt signaling pathway and STZ-induced diabetic rats
【24h】

Moringa concanensis Nimmo ameliorates hyperglycemia in 3T3-L1 adipocytes by upregulating PPAR-gamma, C/EBP-alpha via Akt signaling pathway and STZ-induced diabetic rats

机译:通过AKT信号通路和STZ诱导的糖尿病大鼠通过AKT信号通路和STZ诱导的糖尿病大鼠来改善3T3-L1 adipocytes中的高血糖在3T3-L1 adipocytes中改善高血糖症

获取原文
获取原文并翻译 | 示例
           

摘要

Moringa concanensis Nimmo is a medicinal plant for treating various human illnesses including menstrual pain, high blood pressure, jaundice, inflammation, pain, fever, sore eyes, and cholesterol in Indian folk medicine. Despite its versatility, its antihyperglycemic mechanism of action (in vitro and in vivo) remains unclear. Therefore, in this study we developed the possible antihyperglycemic mechanism of action in 3T3-L1 cells by evaluating mRNA and protein expression, which are associated with adipogenesis and lipogenesis (insulin sensitizer). Also, the antihyperglycemic activity of the ethanolic extract of M. concanensis Nimmo leaves (EEMCN) was evaluated on glucose, insulin, biochemical, and lipid profile in experimental diabetic rat models induced with streptozotocin (STZ). Results showed that EEMCN leaves enhanced lipid accumulation in 3T3-L1 cells, as assessed by Oil Red O staining, and upregulated gene expression level of PPAR-gamma, C/EBP-alpha, t-SREBP, FAS, Glut-4, adipogenin, DAG, and LPL through Akt signaling in 3T3-L1 cells. Also, EEMCN treatment increased body weight and insulin level and lowered blood glucose, HbA1c, amylase, and lipid profile level in STZ-induced diabetic rats. In conclusion, EEMCN possesses in vivo antidiabetic potential, having such efficacy through a mechanism of action that involves antihyperglycemic, hypoglycemic, and potential insulin sensitizer (PPAR-gamma, C/EBP-alpha/Akt over expression) action.
机译:Moringa Concanensis Nimmo是一种治疗各种人类疾病,包括月经疼痛,高血压,黄疸,炎症,疼痛,发烧,眼睛和印度民间胆固醇的药用植物。尽管它具有通用性,其抗血糖作用机制(体外和体内)仍然不清楚。因此,在本研究中,我们通过评估mRNA和蛋白质表达,在3T3-L1细胞中制定了可能的抗血糖作用机制,其与脂肪发生和脂肪生成相关(胰岛素敏化剂)。此外,在用链脲佐菌素(STZ)诱导的实验糖尿病大鼠模型中的葡萄糖,胰岛素,生物化学和脂质分布评估了M. concanensis nimmo叶(EEMCN)的乙醇提取物的抗血糖糊化活性。结果表明,由于油红澳染料评估,eEMCN留下增强的脂质积累,并通过油红澳染色评估,以及PPAR-Gamma,C / EBP-α,T-Srebp,Fas,Glut-4,Adipogenin的上调基因表达水平, DAG和LPL通过3T3-L1细胞中的AKT信号传导。此外,EEMCN治疗在STZ诱导的糖尿病大鼠中增加了体重和胰岛素水平和降低的血糖,HBA1C,淀粉酶和脂质曲线水平。总之,EEMCN具有体内抗糖尿病潜力,通过涉及抗血糖,降血性和潜在胰岛素敏化剂(PPAR-Gamma,C / EBP-α/ AKT过度表达)作用的作用机制具有此类疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号